Beyond safety: adverse events and unanticipated advantages of SGLT2 inhibitors [0.03%]
超越安全性：钠-葡萄糖协同转运蛋白2抑制剂的不良事件及意外优势
Lorenzo Falsetti,Nicola Tarquinio,Luciano Mucci et al.
Lorenzo Falsetti et al.
Background: Sodium-glucose transporter 2 inhibitors (SGLT2i) are widely used for diabetes management and have demonstrated benefits in treating acute and chronic heart failure (HF) and chronic kidney disease (CKD). Their ...
Trough concentration of voriconazole and its association with central nervous system toxicity in patients with hematologic malignancies: a retrospective cohort study [0.03%]
伏立康唑 troughs 与血液系统恶性肿瘤患者的中枢神经系统毒性之间的相关性：回顾性队列研究
Qinghua Zhang,Junwei Chen,Wenming Tan et al.
Qinghua Zhang et al.
Marine L Andersson,Johan Fastbom,Bengt Danielsson et al.
Marine L Andersson et al.
The association between proton pump inhibitor use and the risk of mortality in patients with kidney disease: a systematic review and meta-analysis [0.03%]
肾脏疾病患者使用质子泵抑制剂与死亡风险之间的关联：系统评价和meta分析
Ilsoo Park,Hyun Jin Song,Hyun-Ju Seo
Ilsoo Park
Background: Use of proton pump inhibitor (PPI) has been associated with adverse health outcomes, including increased risk of all-cause mortality. Evidence suggests that individuals with kidney disease who use PPIs may exp...
Colistin-induced acute kidney injury in neonates with sepsis and its association with plasma colistin concentration: a prospective cohort study [0.03%]
碳氢霉烯致新生儿脓毒症急性肾损伤及其与血浆碳氢霉烯浓度相关性的一项前瞻性队列研究
Ramya Kagnur,Kanya Mukhopadhyay,Nusrat Shafiq et al.
Ramya Kagnur et al.
Effect of transporter gene polymorphisms and valproate co-medication on the steady-state disposition of lamotrigine and their effect on efficacy in adults with epilepsy [0.03%]
多态性及丙戊酸联合用药对拉莫三嗪 steadystate 体内过程的影响及其疗效分析
Changsong Wu,Rui He,Jianghuan Zheng et al.
Changsong Wu et al.
Cost-effectiveness analysis of anti-VEGF drugs in the treatment of visual impairment due to diabetic macular edema: A systematic review [0.03%]
抗VEGF药物治疗糖尿病黄斑水肿所致视力损害的经济学分析系统评价
Mojtaba Hasoumi,Vahid Alipour,Hamid Ahmadieh et al.
Mojtaba Hasoumi et al.
Prevalence of substances with OATP1B1 inhibitory properties in individual case safety reports of suspected statin-associated myopathy - an analysis of Swiss pharmacovigilance data [0.03%]
瑞士药物警戒数据分析中含OATP1B1抑制属性物质的他汀相关肌病疑似病例报告中的流行率分析
Céline K Stäuble,Valeriu Toma,Thomas Stammschulte et al.
Céline K Stäuble et al.
Purpose: Statin associated musculoskeletal symptoms (SAMS) are common adverse drug reactions reported by 20% of statin users and are assumed to be dose dependent. The organic anion transporting polypeptide 1B1 (OATP1B1), ...
Clinical pharmacology of antiplatelet drugs: implications for personalized therapy [0.03%]
抗血小板药物的临床药理学：个性化治疗的意义
Surasak Wichaiyo
Surasak Wichaiyo